Vaccine Research

R&D collaboration with Antigen Express announced for SARS vaccine development

Published in Vaccine Weekly, June 18th, 2003

Generex Biotechnology Corp. (GNBT) announced an agreement in principle for a collaboration to develop SARS (severe acute respiratory syndrome) vaccines utilizing the company's proprietary drug delivery and formulation technology.

Generex will collaborate with privately owned Antigen Express, which will use its proprietary Ii protein suppression and Ii-Key peptide vaccine-enhancing technologies in the development of SARS vaccines. Antigen develops a range of therapeutics for the treatment of cancer, autoimmune, infectious, and allergic diseases. The agreement is subject to the completion of due diligence and formal documentation.

Generex's scientists...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (2003-06-18)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry